COMPASS (rivaroxaban alone), 2017 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of rivaroxaban versus aspirin in Patients With Coronary or Peripheral Artery Disease

        Z

NCT01776424    



Studied treatment Rivaroxaban 2.5 mg twice daily alone
Control treatment aspirin 100 mg once daily

3 arms rivaroxaban and aspirin, rivaroxaban alone, aspirin alone



Patients Patients With Coronary or Peripheral Artery Disease
Size27400
smokers (%)
familly history of CHD
Systolic blood pressure (mmhg)
Cholesterol total (mmol/L)



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI0,22,01,0

Links

NEJM

ClinicalTrial.gov record NCT01776424



Registering number NCT01776424 (see trial on clinicaltrials.gov)
Code Name